FocusPolicy

Bench-to-Bench Bottlenecks in Translation

See allHide authors and affiliations

Science Translational Medicine  20 Aug 2014:
Vol. 6, Issue 250, pp. 250fs32
DOI: 10.1126/scitranslmed.3009000
  • Fig. 1 On second thought.

    (A) Percentage of first-licenses and second-licenses, for patent/license pairs across a variety of disease indications. (B) Changes in disease indications from first- to second-licenses for patent/license pairs. Total change, different disease; add, new disease indications added; subtract, disease indications eliminated. (C) Percentage of first-licenses, second-licenses, or both (for patents on potential therapies) that were directed toward cancer or CNS, cardiovascular, or infectious diseases. “Included in first- and second-license,” disease indication listed in first- and second-license; “first-license only,” disease indication listed only in first-license; “second-license only,” disease indication listed only in second-license.

    CREDIT: V. ALTOUNIAN/SCIENCE TRANSLATIONAL MEDICINE

Supplementary Materials

  • www.sciencetranslationalmedicine.org/cgi/content/full/6/250/250fs32/DC1

    Introduction, data sources, methods

    Table S1. Stage of therapeutic development.

    Table S2. Stage of therapeutic development for patents in both first- and second-licenses.

    Table S3. Disease category.

    Table S4. Percent of first- and second-licenses excluding blank.

    Table S5. Disease indications in second-licenses when first-licenses listed cancer.

    Table S6. Second-licenses that list cancer; source of first-licenses.

    Table S7. First-licenses that list CNS diseases; disease indications in second-licenses.

    Table S8. Second-licenses that list CNS diseases and the source of first licenses.

    Appendix

  • Supplementary Material for:

    Bench-to-Bench Bottlenecks in Translation

    Matthew J. Higgins, Jerry Thursby, Marie Thursby*

    *Corresponding author. E-mail: marie.thursby@scheller.gatech.edu

    Published 20 August 2014, Sci. Transl. Med. 6, 250fs32 (2014)
    DOI: 10.1126/scitranslmed.3009000

    This PDF file includes:

    • Introduction, data sources, methods.
    • Table S1. Stage of therapeutic development.
    • Table S2. Stage of therapeutic development for patents in both first- and second-licenses.
    • Table S3. Disease category.
    • Table S4. Percent of first- and second-licenses excluding blank.
    • Table S5. Disease indications in second-licenses when first-licenses listed cancer.
    • Table S6. Second-licenses that list cancer; source of first-licenses.
    • Table S7. First-licenses that list CNS diseases; disease indications in second-licenses.
    • Table S8. Second-licenses that list CNS diseases and the source of first licenses.
    • Appendix

    [Download PDF]

Navigate This Article